

MTPConnect

Australia's Life Sciences
Innovation Accelerator

TTRA TARGETED TRANSLATION
RESEARCH ACCELERATOR
DIABETES + CARDIOVASCULAR DISEASE

INFORMATION SESSION: TTRA Devices

Wednesday 4 March 2026 | 1:00PM – 2:00PM AEDT

MTPConnect

→ Championing a sector-led approach to accelerating the growth of the
medical technology, biotechnology and pharmaceutical ecosystem in Australia

Welcome & Acknowledgement of Country



Lauren Kelly
Senior Director | TTRA Program

Acknowledgement of Country


MTPConnect recognises the First Peoples of this nation and their ongoing connection to culture and Country. We acknowledge Aboriginal and Torres Strait Islander Peoples as the Traditional Owners, Custodians and Lore Keepers of the world's oldest living culture and pay respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander people.

Jordan Lovegrove,
Unified Collaboration & Innovation (2024)

Jordan Lovegrove, Ngarrindjeri artist encapsulates the essence of Australia as a hub of rich biodiversity, scientific innovation, healing, and unified collaboration.

At its heart, the artwork features a large meeting place symbolising the convergence of minds, representing the collaborative spirit embodied by Australian scientists and innovators.

Throughout the piece, smaller gathering spaces dot the landscape, symbolising diverse communities and individuals uniting in collaboration. These smaller meeting places echo the broader theme of coming together for shared goals and mutual growth.



Housekeeping

QUESTIONS

- Please enter questions in the **Q&A BOX** (*not the CHAT box*)
- You can **SUBMIT ANONYMOUSLY** – Just click the checkbox
- **Have the same question as someone else?**
You can UPVOTE a question by clicking the THUMBS UP

RECORDING

- This webinar will be recorded and slides published shortly– We'll email you when they're ready!
- View the **ON-DEMAND VIDEO** at mtpconnect.org.au/webinars
- Listen by subscribing to **THE MTPCONNECT PODCAST**
Available on Apple Podcasts, Spotify and on our website




For information please contact
ACCELERATOR@MTPCONNECT.ORG.AU

MTPConnect's Accelerator Team



Lauren Kelly

Senior Director



Dr Dharmica Mistry

Senior Medtech Commercialisation Specialist



Dr Erin McAllum

Associate Director



Dr Elise Needham

Senior Therapeutics Commercialisation Specialist



Jane Zheng

Events and Operations Coordinator



Dr Andionne Parlade

Commercialisation Specialist

Accelerating growth of Australia's medical products sector

As Australia's Life Sciences Innovation Accelerator, MTPConnect supports innovators to help bring life-saving medical products from bench to bedside

- Delivering Accelerator programs for start-ups and SMEs to grow, scale and prosper
- Industry Partner Organisation for the Industry Growth Program
- Improving access to global supply chains and international markets through trade delegations and MOUs
- Providing connections, information and opportunities for startups and SMEs developing medical products
- Advisory and program design services for the innovation sector



MTPConnect's Accelerator Programs

Our accelerator programs support the development of cutting-edge medical technology, biotechnology and pharmaceutical innovations, with more than A\$210million invested so far in over 200 projects



MTPConnect's \$7.5 Billion Impact

With our focus on increasing collaboration and commercialisation, MTPConnect has secured matching industry contributions and substantial flow-on industry investment to amplify grant funding and help drive projects through the early stages of clinical development and maximise the chances for commercialisation success.

- \$210 million in sector support funds across multiple funding initiatives
- Supporting over 200 innovation projects
- Yielded \$1.3 billion in additional industry contributions and flow-on investment
- The overall economic impact of MTPConnect activities is a total attributable return of \$7.5 billion



2,070
New Products Invented
or Progressed



2,500
New Jobs Created



745,000+
Lives Positively Impacted
Through Clinical Trials

LET'S GET TO KNOW YOU...



Please answer all POLL questions and hit [SUBMIT](#)

TTRA

TARGETED TRANSLATION
RESEARCH ACCELERATOR
DIABETES + CARDIOVASCULAR DISEASE

Powered by **MTPConnect**

Australia's diabetes & cardiovascular
disease innovation accelerator

Non-dilutive funding

Bespoke commercialisation & technical support

Access to a network of clinical, lived experience & industry experts

Support for accessing global markets & supply chains

IMPACT PARTNERS



PAST PARTNERS



ANDHealth
Australia's National Digital Health Initiative



Australian Centre
for Health Services
Innovation



LOWITJA
INSTITUTE



MEDICAL DEVICE
PARTNERING
PROGRAM



TTRA

TARGETED TRANSLATION
RESEARCH ACCELERATOR
DIABETES + CARDIOVASCULAR DISEASE

MEDICAL DEVICES



THERAPEUTICS



DIGITAL HEALTH



MODELS OF CARE



RESEARCH CENTRES



The logo for TTRA, with 'T' in teal and 'TRA' in white.

TARGETED TRANSLATION
RESEARCH ACCELERATOR
DIABETES + CARDIOVASCULAR DISEASE

Powered by **MTPConnect**

TTRA Devices Round 2

EOI NOW OPEN



APPLY BY
30 MARCH 2026


TTRA Devices Round 2



Dr Andionne Parlade
Commercialisation Specialist

TTRA Devices Round 2 Opportunity

Supporting SMEs to accelerate promising **medical devices** that reduce the burden of cardiovascular disease and complications of diabetes for patients, carers, families and communities



Up to \$1M
Non-dilutive TTRA
Funding



24 months
maximum term



Nurture health and
medical innovations
to reach commercial
proof-of-concept



Mentoring &
Guidance



Access to a
network of experts

Eligibility

Lead applicants must:

- Be a registered Australian-based **for-profit business**
- Be incorporated in Australia
- Have an **Australian Business Number (ABN)**
- Have **less than 200 employees**
- Not be a technology transfer office/mechanism for a university or MRI

Demonstrated capacity to match the **co-contribution** requirement

Product/solution must be a **medical device** that addresses **cardiovascular disease or the complications of diabetes (type 1 or 2)**

Product/solution must meet the **minimum stage of development** requirement (TRL 4)


Applicants must **control or have legal right to access and use relevant IP**

- Background IP, Project IP, not infringing on third party IP

Eligibility: co-contribution requirement

Investment Request	Required <u>Cash</u> Co- Contribution : TTRA funding	Example
\$200,000 - \$500,000	1:4	TTRA Investment = \$450,000 Cash co-contribution = \$112,500 Total Budget = \$562,500
\$500,001 - \$1,000,000	1:2	TTRA Investment = \$850,000 Cash co-contribution = \$425,000 Total Budget = \$1,275,000

Application Process





TTRA Drugs and Devices

- EOI now open!
- Submissions will close at **16:00 AEDT on 30 March 2026**

MTPConnect is delivering a new \$28.5 million investment for TTRA Drugs and Devices for the MRFF, injecting much-needed funding and support for Australian small to medium enterprises (SMEs), and which builds on the legacy of the inaugural research accelerator program.

The objective of TTRA Drugs and Devices is to accelerate development and commercialisation of promising drugs and medical devices into products that can reduce the burden of cardiovascular disease and complications of diabetes for patients, carers, families, and community.

TTRA Drugs and Devices is delivered in collaboration with Impact Partners CSL and Roche Diagnostics Australia who bring additional industry knowledge, market expertise and commercialisation experience.

New TTRA Devices Funding Call

[FUNDING GUIDELINES](#)

[APPLY NOW](#)

Expressions of interest for the new TTRA Devices Round 2 investment opportunity are now open, providing up to \$1 million to help eligible Australian start-ups, spin-outs and SMEs develop innovative preventative, diagnostic, therapeutic and/or disease management devices for cardiovascular disease and the complications of diabetes (type 1 and type 2).

The maximum funding term for TTRA Devices is 24 months, with projects completing no later than 30 September 2028.


Applicants will be required to provide a cash co-contribution relative to the value of the TTRA funding request to be eligible. Additional in-kind or cash contributions above this threshold will be viewed favourably.

Expressions of interest for this opportunity are now open. Applications can only be submitted through MTPConnect's grants portal, and must be received by 30 March 2026, 16:00 AEDT.



SmartyGrants - Notice of Intent

NOI



MTPConnect
Australia's Life Sciences
Innovation Accelerator

Not logged in. [Log in](#) Current Rounds

TTRA Devices Round 2 - Notice of Intent

[Start a submission](#) [Preview the form](#) [Download preview form](#)

Submissions are now being accepted. Submissions close at 9:00AM 30 March 2026 (AEDT).

IMPORTANT: Please read information below to assist you in completing your application online.

BEFORE YOU BEGIN

Welcome to the **MTPConnect** online grant application portal, powered by [SmartyGrants](#).

You may begin anywhere in this application form. Please ensure you save as you go.


For queries about the guidelines, deadlines, or questions in the form, please contact us via email accelerator@mtconnect.org.au and quote your submission number.

[Click here to view the guidelines.](#)

If you need more help using this form, download the [Help Guide for Applicants](#) or check out [Applicant Frequently Asked Questions \(FAQ's\)](#)



EOI



MTPConnect
Australia's Life Sciences
Innovation Accelerator

Not logged in. [Log in](#) Current Rounds

TTRA Devices Round 2 - Expression of Interest

[Start a submission](#) [Preview the form](#) [Download preview form](#)

Submissions are now being accepted. Submissions close at 4:00PM 30 March 2026 (AEDT).

IMPORTANT: Please read information below to assist you in completing your application online.

BEFORE YOU BEGIN

Welcome to the **MTPConnect** online grant application portal, powered by [SmartyGrants](#).

You may begin anywhere in this application form. Please ensure you save as you go.

For queries about the guidelines, deadlines, or questions in the form, please contact us via email accelerator@mtconnect.org.au and quote your submission number.

[Click here to view the guidelines.](#)

If you need more help using this form, download the [Help Guide for Applicants](#) or check out [Applicant Frequently Asked Questions \(FAQ's\)](#)

Selection Criteria



Dr Dharmica Mistry
Senior Medtech Commercialisation
Specialist

TTRA Drugs and Devices Selection Criteria

Challenge &
Solution



25%

Technical
Merit



25%

Project
Plan



15%

Translation &
Commercialisation



10%

Team &
Capabilities



25%

Selection Criteria – Challenge & Solution

Challenge & Solution



25%

- Clear articulation of how the proposed product/solution will address a **community/end-user identified unmet or underserved need** for cardiovascular disease or the complications of diabetes (types 1 or 2)
- Clearly described **value proposition**
- Clear **competitive advantage and differentiation** over current and emerging solutions
- Consideration has been given to achieve and/or enhance equitable health service delivery and/or access.

Selection Criteria – Technical Merit

Technical Merit



25%

- **Technical and stakeholder validation** of the product, including preclinical benchtop and/or animal and/or clinical evidence for proof-of-concept, efficacy and safety
- Include a comparator to the gold standard or standard of care where possible
- Evidence of **stakeholder engagement and feedback from people with lived experience**, clinicians and /or payers, demonstrating co-design and development of the device

Selection Criteria – Project Plan

Project Plan



15%

- Clearly justified activities, deliverables, milestones, go/no-go decision points and outcomes
- Proposed activities are on the critical path towards commercial proof-of-concept or other important translation **inflection points**
- Includes a feasible and appropriate plan **for consumer and lived experience involvement**
- Key **project risks** are identified, with mitigation strategies

Selection Criteria – Translation & Commercialisation

Translation & Commercialisation



10%

- Secured appropriate IP protection or adequately described a robust **IP strategy**
- Proposed **clinical development plan** is appropriate and feasible
- Credible **regulatory pathway**
- Feasible **business model and commercialisation strategy** clearly outlined

Selection Criteria – Team & Capabilities

Team & Capabilities



25%

- The team has the **requisite experience and demonstrated track record**
- The team outlined is **diverse** (including, but not limited to, gender, career stage, lived experience and/or different cultural backgrounds)
- The team has access to the requisite **infrastructure** and relevant co-contributions to achieve the milestones.

MTPConnect

Australia's Life Sciences
Innovation Accelerator

Questions?



- Please enter them in the Q&A box
- You can tick the ANONYMOUS checkbox
- UPVOTE existing questions

MTPConnect

→ Championing a sector-led approach to accelerating the growth of the
medical technology, biotechnology and pharmaceutical ecosystem in Australia



TTRA Drugs and Devices

- EOI now open!
- Submissions will close at **16:00 AEDT on 30 March 2026**



For information please contact
ACCELERATOR@MTPCONNECT.ORG.AU

MTPConnect is delivering a new \$28.5 million investment for TTRA Drugs and Devices for the MRFF, injecting much-needed funding and support for Australian small to medium enterprises (SMEs), and which builds on the legacy of the inaugural research accelerator program.

The objective of TTRA Drugs and Devices is to accelerate development and commercialisation of promising drugs and medical devices into products that can reduce the burden of cardiovascular disease and complications of diabetes for patients, carers, families, and community.

TTRA Drugs and Devices is delivered in collaboration with Impact Partners CSL and Roche Diagnostics Australia who bring additional industry knowledge, market expertise and commercialisation experience.

New TTRA Devices Funding Call

FUNDING GUIDELINES

APPLY NOW

Expressions of interest for the new TTRA Devices Round 2 investment opportunity are now open, providing up to \$1 million to help eligible Australian start-ups, spin-outs and SMEs develop innovative preventative, diagnostic, therapeutic and/or disease management devices for cardiovascular disease and the complications of diabetes (type 1 and type 2).

The maximum funding term for TTRA Devices is 24 months, with projects completing no later than 30 September 2028.

Applicants will be required to provide a cash co-contribution relative to the value of the TTRA funding request to be eligible. Additional in-kind or cash contributions above this threshold will be viewed favourably.

Expressions of Interest for this opportunity are now open. Applications can only be submitted through MTPConnect's grants portal, and must be received by 30 March 2026, 16:00 AEDT.



<https://mtpconnect.smartygrants.com.au/>



MTPConnect

Australia's Life Sciences
Innovation Accelerator

CONTACT US FOR FURTHER
INFORMATION

Phone

+61 3 9070 8298

Email

info@mtpconnect.org.au

Get Social



Follow
MTPConnect



Subscribe on
Apple Podcasts

MTPCONNECT.ORG.AU

Timeline

Expected key dates

Research Projects Application	Start Date	End Date
EOI Application	23 Feb 2026	30 Mar 2026
EOI Outcomes		Early May 2026
Due Diligence Consultation	Early May 2026	Late May 2026
Due Diligence Consultation Outcomes		Early Jun 2026
Full Proposal Application	Early Jun 2026	Early Jul 2026
Full Proposal Outcomes		Mid Aug 2026
Contracting	Early Sep 2026	Late Sep 2026
Investment Term	1 Oct 2026	Project dependent

Devices

As defined by the Therapeutic Goods Act 1989, a medical device is any instrument, apparatus, appliance, material or other article (whether used alone or in combination, and including the software necessary for its proper application) intended, by the person under whose name it is or is to be supplied, to be used for human beings for the purpose of one or more of the following:

- diagnosis, prevention, monitoring, treatment or alleviation of disease
- diagnosis, monitoring, treatment, alleviation of or compensation for an injury or disability
- investigation, replacement or modification of the anatomy or of a physiological process
- control of conception
- and that does not achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, but that may be assisted in its function by such means.

Software (including mobile apps) is a medical device if it fits within the definition of a medical device above (e.g., an app that organises and tracks a person's health information and analyses this information to diagnose disease). Software or mobile apps that are simply sources of information or tools to manage a healthy lifestyle do not meet the definition of a medical device.

Products/solutions that are a drug/device combination are eligible, as long as there is *novelty and differentiation* of the device component. This opportunity cannot support development of drugs. If you are developing a combination drug/device, please contact MTPConnect at accelerator@mtpconnect.org.au prior to submitting your EOI to confirm eligibility.




Figure 1. Intellectual Property eligibility flow chart.

Background IP refers to existing IP that belongs to, or is under the control of a Party, which the Party provides to support the TTRA Devices project.

Project IP refers to any new IP created during the TTRA Devices project but excludes Background IP.

If the applicant organisation is a subsidiary of an international company, the Australian applicant SME must have the right to commercialise the project IP in at least Australia and must be able to demonstrate substantial benefit flow to Australia (e.g. jobs, skills, investment etc). If you are an Australian subsidiary, please contact MTPConnect to confirm your eligibility at accelerator@mtpconnect.org.au.

Division 2—Interpretation

41BD What is a *medical device*

(1) A *medical device* is:

- (a) any instrument, apparatus, appliance, software, implant, reagent, material or other article (whether used alone or in combination, and including the software necessary for its proper application) intended, by the person under whose name it is or is to be supplied, to be used for human beings for the purpose of one or more of the following:
 - (i) diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of disease;
 - (ii) diagnosis, monitoring, treatment, alleviation of or compensation for an injury or disability;
 - (iii) investigation, replacement or modification of the anatomy or of a physiological or pathological process or state;
 - (iv) control or support of conception;
 - (v) in vitro examination of a specimen derived from the human body for a specific medical purpose;and that does not achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, but that may be assisted in its function by such means; or
- (aa) any instrument, apparatus, appliance, software, implant, reagent, material or other article specified under subsection (2A); or
- (ab) any instrument, apparatus, appliance, software, implant, reagent, material or other article that is included in a class of instruments, apparatus, appliances, software, implants, reagents, materials or other articles specified under subsection (2B); or
- (b) an accessory to an instrument, apparatus, appliance, software, implant, reagent, material or other article covered by paragraph (a), (aa) or (ab); or
- (c) a system or procedure pack.

Note: Declarations under subsection (3) exclude articles from the scope of this definition. Declarations under section 7 can also have this effect: see subsection 7(4).

- (2) For the purposes of paragraph (1)(a), the purpose for which an instrument, apparatus, appliance, software, implant, reagent, material or other article (the *main equipment*) is to be used is to be ascertained from the information supplied, by the person under whose name the main equipment is or is to be supplied, on or in any one or more of the following:
 - (a) the labelling on the main equipment;
 - (b) the instructions for using the main equipment;
 - (c) any advertising material relating to the main equipment;
 - (d) technical documentation describing the mechanism of action of the main equipment.
- (2A) The Secretary may, by notice published in the *Gazette* or on the Department's website, specify a particular instrument, apparatus, appliance, software, implant, reagent, material or other article for the purposes of paragraph (1)(aa). The notice is not a legislative instrument. The notice takes effect on the day on which the notice is published in the *Gazette* or on the Department's website or on such later day as is specified in the notice.
- (2B) The Secretary may, by legislative instrument, specify a particular class of instruments, apparatus, appliances, software, implants, reagents, materials or other articles for the purposes of paragraph (1)(ab).
- (3) The Secretary may, by legislative instrument, declare that a particular instrument, apparatus, appliance, software, implant, reagent, material or other article, or that a particular class of instruments, apparatus, appliances, software, implants, reagents, materials or other articles, are not, for the purposes of this Act, medical devices.

Note: A declaration under this section does not stop articles from being therapeutic goods.

[Home](#) > [Resources and guidance](#) > [Decision trees](#)

Is my product a medical device?

This tool will help you determine if your product is a medical device.

Last updated: 21 June 2024

[Listen](#) [Print](#) [Share](#)

<https://www.tga.gov.au/resources/decision-trees/my-product-medical-device#node-335>